If you have ever abandoned a prescription eye drop because it stung, blurred your vision, or left a metallic taste in your mouth, a new class of steroid-free drop may eventually offer an alternative. Reproxalap, an investigational therapy developed by Aldeyra Therapeutics, produced fewer side effects and better immediate comfort than lifitegrast, the active ingredient in the widely prescribed drop Xiidra, in a direct crossover comparison among patients with chronic dry eye disease. In a separate large-scale Phase 3 safety trial, 757 patients used reproxalap for up to 12 months with no treatment-related serious adverse events.
The findings arrive as dry eye disease surges in prevalence. A 2021 meta-analysis in BMJ Open Ophthalmology linked prolonged digital screen use to significantly higher rates of dry eye symptoms, and the American Academy of Ophthalmology now lists the condition among the most frequent reasons adults seek eye care. Current prescription options, including cyclosporine (sold as Restasis and Cequa), lifitegrast (Xiidra), and the nasal spray varenicline (Tyrvaya), help many patients but come with tolerability trade-offs that drive high dropout rates.
What the trials show
The strongest safety evidence comes from a peer-reviewed Phase 3 trial published in Ophthalmology and Therapy. That study enrolled 757 patients, randomizing 504 to reproxalap and 253 to a vehicle control. One cohort was followed for 6 weeks; a second cohort extended to 12 months. Across both groups, no treatment-related serious adverse events were recorded. The most common complaint was a brief, mild stinging sensation at the instillation site that resolved on its own.
Reproxalap works through a mechanism unlike anything currently on the market. It is a RASP (Reactive Aldehyde Species) inhibitor, meaning it neutralizes inflammatory aldehyde molecules that accumulate in the tear film. That is a fundamentally different approach from cyclosporine, which broadly suppresses immune activity on the ocular surface, or lifitegrast, which blocks a specific protein involved in T-cell adhesion. A Phase 2a randomized, double-masked trial published in Clinical Ophthalmology first established the mechanism’s relevance to dry eye symptoms over roughly 28 days, testing multiple formulations and doses before larger trials began.
The head-to-head tolerability data add a practical dimension. A crossover trial published in Clinical Ophthalmology directly compared reproxalap 0.25% against lifitegrast 5% in dry eye patients. Because each patient tried both drops and served as their own control, the design reduces the variability that comes from comparing separate groups. Researchers measured post-instillation comfort, including stinging, blurring, and dysgeusia, the bitter or metallic taste that is one of the most common reasons patients stop using Xiidra. Reproxalap produced less of each complaint immediately after instillation.
Lifitegrast’s own clinical record is well established. Its efficacy was demonstrated in the OPUS-1 and OPUS-2 randomized controlled trials, which measured symptom endpoints such as eye dryness scores and objective signs including inferior corneal staining. A published analysis of those trials helped secure FDA approval and made lifitegrast a standard prescription option. The crossover comparison with reproxalap matters precisely because it was measured against a drug that already cleared that regulatory bar.
What remains uncertain
Several gaps separate these trial results from everyday clinical practice. The 12-month cohort in the Phase 3 study tracked safety, not long-term efficacy. Whether reproxalap continues to relieve dryness symptoms beyond the shorter treatment windows tested in earlier efficacy studies has not been reported in any published trial. Patients who rely on drops daily for years need durability data, and that evidence does not yet exist.
Adherence outside controlled settings is another open question. Dry eye drops are notoriously hard to use consistently. Patients forget doses, dislike the sensation, or stop refilling prescriptions when costs rise. None of the published reproxalap trials include real-world persistence or adherence figures, so the comfort advantage seen in the crossover study may or may not translate into patients actually sticking with the drop longer than they stick with lifitegrast or cyclosporine.
Pricing and insurance coverage are entirely unaddressed in the clinical literature. Xiidra already carries a high list price, and many patients pay significant out-of-pocket costs even with coverage. If reproxalap reaches the market at a comparable or higher price, the comfort advantage could be offset by access barriers.
Regulatory status also needs careful framing. Aldeyra Therapeutics has advanced reproxalap through Phase 2 and Phase 3 clinical programs, and the U.S. Food and Drug Administration accepted the company’s New Drug Application. However, as of June 2026, no formal approval has been confirmed in published trial records or FDA databases. Readers should treat reproxalap as an investigational drug until an official approval announcement appears.
How to weigh the evidence
The data supporting reproxalap fall into distinct tiers, and each tier answers a different question.
The Phase 3 safety study is the largest and most recent primary source. It answers whether the drop is safe for extended use, and the answer so far is yes, with a substantial sample size and follow-up reaching 12 months. The crossover trial answers a narrower but highly practical question: does reproxalap feel better than lifitegrast right after you put it in your eye? The answer, based on the crossover design, is also yes, though the study measured tolerability, not whether one drop controls dryness better than the other over weeks or months.
A smaller chamber trial using 63 patients in a controlled environment found that reproxalap improved ocular redness, tear production measured by Schirmer score, and multiple symptom endpoints compared with vehicle. Those objective efficacy signals are encouraging, but the small sample and artificial exposure conditions mean the results need confirmation in larger, real-world populations.
Earlier Phase 2 work, including a trial registered on ClinicalTrials.gov, followed patients for roughly a month and tracked changes in symptom scores, ocular surface staining, and tear production. These studies support the idea that blocking reactive aldehyde species can reduce inflammation on the eye’s surface, but they do not establish how reproxalap performs over the multiyear timelines that matter for a chronic disease.
What this means for patients and clinicians
For eye care providers, the current body of evidence suggests a clean safety profile and a likely comfort advantage over lifitegrast at the moment of instillation. That could be particularly relevant for patients who have cycled through other prescription drops and quit because of burning, blurred vision, or unpleasant taste.
For patients, the takeaway is more measured. Reproxalap appears well tolerated in studies completed so far, and its novel mechanism addresses inflammation through a pathway no approved drop currently targets. But it remains investigational, without long-term effectiveness data, confirmed FDA approval, or any public pricing information.
The questions that will ultimately determine whether reproxalap changes daily life for the millions of people whose eyes burn after hours in front of a screen are not scientific ones. They are logistical: Will insurers cover it? Will pharmacies stock it? Will patients keep filling the prescription month after month? Until those answers arrive, reproxalap occupies a space that is genuinely promising but not yet proven in the ways that matter most outside a clinical trial.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
